Market Access Focus Kintiga is Europe’s independent specialist pharmaceutical and biotechnology management consultancy specializing in maximizing product portfolio value and facilitating patient access across complex regulatory and payer environments, signaling a sales opportunity for expanded market access services and payer strategy partnerships.

Recent Acquisitions Recent activity includes the acquisition of MAP Patient Access Limited by its portfolio company and Biopharmics, indicating a growth trajectory and potential cross-sell of consulting and software solutions to integrated market access platforms.

Online Platform An evolving MAP Online roadmap aims to improve navigation and efficiency, presenting an opportunity to offer digital subscription enhancements, e-learning modules, and data-driven market access tools to their broad European pharmaceutical and biotech client base.

Financial Scale With revenue in the low to mid single-digit millions and a lean employee base, Kintiga could benefit from scalable, cost-effective technology, consulting automation, and partner ecosystems to grow services without proportional headcount expansion.

Strategic Partnerships The collaboration with BIAL Pharma UK and the firm’s role in supporting access across Europe positions Kintiga as a gateway for partnerships with mid-market and niche pharma/biotech firms seeking market access and commercialization support in multiple jurisdictions.